Alfred Lim
Director of Lab Research Etcembly
Alfred is Director of Lab Research at Etcembly, where he leads the development of new T cell engager drug candidates from discovery through to preclinical characterization and translational development. He was previously Head of Discovery at Theolytics and was responsible for candidate optimisation and lead nomination across the different pipeline programs. Alfred trained in immunology at the MRC Laboratory of Molecular Biology, Cambridge and holds a PhD in Molecular Immunology from the University of Cambridge.
Seminars
Wednesday 10th December 2025
Designing Potent TCR-based T-Cell Engagers for Cancer Immunotherapy with Generative AI
4:30 pm
- Applying our proprietary machine learning platform, EMLy, for TCR discovery leading and affinity enhancement, leading to the development of potent and safe TCR-based T-cell engagers
- Leveraging AI to optimise multi-specific modalities, to enhance immune activation and efficacy against solid tumours
- Integrating AI in the design phase to improve solubility, reduce aggregation, and boost protein yield, ensuring candidate molecules are both potent and manufacturable at scale
